8-K: Sonnet BioTherapeutics Reports Fiscal Year 2025 First Quarter Results and Business Update

Sonnet BioTherapeutics announced its financial results for the three months ended December 31, 2024, and provided a business update, highlighting progress in clinical trials and strategic partnerships.

Summary

• Sonnet BioTherapeutics reported a net loss of $3.2 million, or $1.56 per share, for the first quarter of fiscal year 2025, compared to a net loss of $1.2 million, or $2.46 per share, for the same period in 2024.
• The company had cash and cash equivalents of $4.9 million as of December 31, 2024.
• Sonnet is advancing its lead program, SON-1010, in Phase 1 and Phase 1b/2a trials for solid tumors and platinum-resistant ovarian cancer, with topline efficacy data expected in H1 and H2 2025.
• The company is also developing SON-1210 for advanced solid tumors and metastatic pancreatic cancer, with the first patient expected to be dosed in H1 2025.
• A licensing agreement was established with Alkem Laboratories for SON-080 in India in October 2024, and preparations are underway for a Phase 2 clinical trial in DPN in H2 2025.
• The company completed a registered direct offering and concurrent private placement for gross proceeds of $3.9 million in December 2024.
• Sonnet has reorganized its leadership team, promoting Dr. Stephen McAndrew to Chief Business Officer and Donald Griffith to Chief Financial Officer, effective February 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss, there are positive developments in clinical trials, strategic partnerships, and patent grants. The leadership reorganization also suggests a focus on business development and cost control.

Positives

• 48% of evaluable monotherapy patients in the Phase 1 SB101 trial showed stable disease at four months post-initiation of dosing with SON-1010.
• One patient dosed at the maximum tolerated dose (MTD) in the SB101 trial experienced a partial response (PR) with a 45% reduction in tumor size.
• The company has expanded its Phase 1 SB101 clinical study of SON-1010 to add a new cohort to evaluate the effect of SON-1010 in combination with trabectedin.
• A licensing agreement was signed with Alkem Laboratories in October 2024 to develop and commercialize SON-080 in India.
• The company closed a registered direct offering and concurrent private placement for $3.9 million in December 2024.
• Sonnet expects to initiate a clinical trial with first patient dosed for SON-1210 in H1 calendar year 2025.
• The company announced the granting of EU Patent No. EP3583125 B1 covering its FHAB platform technology in January 2025.

Negatives

• Sonnet BioTherapeutics reported a net loss of $3.2 million for the first quarter of fiscal year 2025, which is higher than the $1.2 million loss reported for the same period in 2024.
• The company's cash and cash equivalents stood at $4.9 million as of December 31, 2024, which may necessitate further fundraising activities in the future.

Risks

• The company's forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied.
• Clinical trials may not yield positive results, and regulatory approvals may not be obtained.
• The company's cash runway may be insufficient to fund its operations until profitability is achieved.
• Competition from other biotechnology companies may impact the company's market opportunity and competitive position.

Future Outlook

The company's focus is on its clinical programs and building on its momentum toward meeting potentially catalytic milestones including a number of key clinical data readouts; all of which they believe have the potential to build shareholder value.

Management Comments

• Pankaj Mohan, Ph.D., Founder and CEO of Sonnet, stated that they have made strides in their Phase 1 SB101 trial with established clinical benefit including a 45% reduction in tumor size by RECIST criteria indicating a partial response and demonstrating the effectiveness of their FHAB platform.
• Pankaj Mohan, Ph.D., Founder and CEO of Sonnet, commented that they continue to bolster their global patent estate and differentiate their plug and play strategy from any competitive technologies that may leverage the beneficial characteristics of binding to human serum albumin.

Industry Context

Sonnet BioTherapeutics is operating in the competitive field of oncology-focused biotechnology companies, developing targeted immunotherapeutic drugs. The company's FHAB platform aims to improve the safety and efficacy of immune modulating biologic drugs. The collaboration with Roche and the Sarcoma Oncology Center highlights the company's efforts to advance its clinical programs and expand its market reach.

Comparison to Industry Standards

• Sonnet's approach of using a Fully Human Albumin-Binding (FHAB) platform is similar to other companies leveraging albumin binding for drug delivery, such as Albumedix, but Sonnet's FHAB is designed to specifically target tumor and lymphatic tissue.
• The clinical trials for SON-1010, particularly the combination therapy with Atezolizumab (Tecentriq) from Roche, are comparable to other immuno-oncology combination studies being conducted by companies like Bristol-Myers Squibb (Opdivo combinations) and Merck (Keytruda combinations).
• The licensing agreement with Alkem Laboratories for SON-080 in India is a common strategy for biotechnology companies to expand their market reach and leverage local expertise, similar to deals made by companies like Glenmark Pharmaceuticals and Dr. Reddy's Laboratories.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and clinical trial results.
• Employees may be affected by the leadership reorganization and the company's focus on business development and cost control.
• Patients with solid tumors, ovarian cancer, and other conditions may benefit from the company's development of targeted immunotherapeutic drugs.
• The licensing agreement with Alkem Laboratories may impact suppliers and distributors in India.

Next Steps

• H1 Calendar Year 2025: Topline Efficacy Data for Phase 1 Solid Tumors (Monotherapy) of SON-1010.
• Q1 Calendar Year 2025: Additional Safety Data for Phase 1b/2a PROC (Combo with Atezolizumab) of SON-1010.
• H2 Calendar Year 2025: RP2D & Topline Efficacy Data for Phase 1b/2a PROC (Combo with Atezolizumab) of SON-1010.
• H2 Calendar Year 2025: Topline Safety Data for Phase 1 STS (Combo with Trabectedin) of SON-1010.
• Q1 Calendar Year 2025: IND Submission for SON-1210.
• H1 Calendar Year 2025: 1st Patient Dosed in Investigator-Initiated Phase 1/2a Study for SON-1210.
• H2 Calendar Year 2025: Initiation of Phase 2 Trial for SON-080.

Key Dates

Keywords

Sonnet BioTherapeutics, SON-1010, SON-1210, SON-080, FHAB platform, clinical trials, immunotherapy, oncology, financial results, licensing agreement, Alkem Laboratories, business update